open access

Vol 4, No 3 (2019)
Original article
Published online: 2019-05-09
Get Citation

The effect of RORa expression on the development of biological malignancy of urinary bladder cancer

Jarosław Starzyński1, Jakub Jóźwicki2, Mateusz Matusiak1, Jakub Dzierżawski1, Jan Misiak3, Anna A. Brożyna14, Wojciech Jóźwicki13
·
Medical Research Journal 2019;4(3):129-135.
Affiliations
  1. Department of Tumour Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Łukaszczyk Memorial Hospital, Romanowskiej 2, 85-796 Bydgoszcz, Poland
  2. Department of Clinical Pathomorphology, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, M. Skłodowskiej-Curie 9, 85-094 Bydgoszcz, Poland
  3. Department of Tumour Pathology and Pathomorphology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, dr. I. Romanowskiej 2, 85-796 Bydgoszcz, Poland
  4. Department of Human Biology, Faculty of Biology and Environment Protection, Nicolaus Copernicus University, Lwowska 1, 87-100 Torun, Poland

open access

Vol 4, No 3 (2019)
ORIGINAL ARTICLES
Published online: 2019-05-09

Abstract

Background: Morbidity and mortality relating to urinary bladder cancer have remained largely unchanged for many years. Similarly, the five-year survival rate in this disease has not improved considerably. New developments in individualized therapy necessitate the search for novel factors that could predict the development of malignancy in UBC. In this study, we provide the first evidence that the expression of ROR alpha transcription factor influences the development of malignancy in UBC. Materials and methods: 105 patients with stage pT1-pT4 urothelial bladder carcinoma who underwent cystectomy were included in the study. 4 μm tissue samples were stained immunohistochemically with a polyclonal anti-RORa antibody. The expression of RORa by the tumor cells (TCs) was assessed by counting TCs with a cytoplasmic and/or nuclear staining for RORa per 1000 TCs. The association between the extent of RORa expression and non-classic differentiation, tumor advancement (pT), grade (G) and regional lymph node spread was analyzed. Results: The cytoplasmic expression of RORa was detected in near all analyzed tumor samples (104/105). The extent of RORa expression was significantly higher in tumors which were more malignant with more propensity for non-classic differentiation and lymph node metastasis. We noted a lower percentage of TCs expressing RORa in poorly differentiated tumors (G3), compared to tumors moderately and higher differentiated (G1/G2). Conclusions: Our results suggest that RORa may play a significant role in the progression of urinary bladder cancer. RORa has a broad spectrum of regulatory activity relating to cell and tissue differentiation the mechanism of which is not fully understood. This study represents another step in the process of understanding the mechanisms of RORa regulation and highlights its potential role as a therapeutic target in urothelial bladder cancer.

Abstract

Background: Morbidity and mortality relating to urinary bladder cancer have remained largely unchanged for many years. Similarly, the five-year survival rate in this disease has not improved considerably. New developments in individualized therapy necessitate the search for novel factors that could predict the development of malignancy in UBC. In this study, we provide the first evidence that the expression of ROR alpha transcription factor influences the development of malignancy in UBC. Materials and methods: 105 patients with stage pT1-pT4 urothelial bladder carcinoma who underwent cystectomy were included in the study. 4 μm tissue samples were stained immunohistochemically with a polyclonal anti-RORa antibody. The expression of RORa by the tumor cells (TCs) was assessed by counting TCs with a cytoplasmic and/or nuclear staining for RORa per 1000 TCs. The association between the extent of RORa expression and non-classic differentiation, tumor advancement (pT), grade (G) and regional lymph node spread was analyzed. Results: The cytoplasmic expression of RORa was detected in near all analyzed tumor samples (104/105). The extent of RORa expression was significantly higher in tumors which were more malignant with more propensity for non-classic differentiation and lymph node metastasis. We noted a lower percentage of TCs expressing RORa in poorly differentiated tumors (G3), compared to tumors moderately and higher differentiated (G1/G2). Conclusions: Our results suggest that RORa may play a significant role in the progression of urinary bladder cancer. RORa has a broad spectrum of regulatory activity relating to cell and tissue differentiation the mechanism of which is not fully understood. This study represents another step in the process of understanding the mechanisms of RORa regulation and highlights its potential role as a therapeutic target in urothelial bladder cancer.

Get Citation

Keywords

RORa; UBC; urothelial bladder cancer; NDN; non-classic differentiation number; ND; non-classic differentiation; lymph node status

About this article
Title

The effect of RORa expression on the development of biological malignancy of urinary bladder cancer

Journal

Medical Research Journal

Issue

Vol 4, No 3 (2019)

Article type

Original article

Pages

129-135

Published online

2019-05-09

Page views

636

Article views/downloads

865

DOI

10.5603/MRJ.a2019.0024

Bibliographic record

Medical Research Journal 2019;4(3):129-135.

Keywords

RORa
UBC
urothelial bladder cancer
NDN
non-classic differentiation number
ND
non-classic differentiation
lymph node status

Authors

Jarosław Starzyński
Jakub Jóźwicki
Mateusz Matusiak
Jakub Dzierżawski
Jan Misiak
Anna A. Brożyna
Wojciech Jóźwicki

References (36)
  1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2): 87–108.
  2. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Centrum Onkologii - Instytut im. odowskiej - Curie, Centrum Onkologii - Instytut im. Marii Skł. ; 2017.
  3. Siegel RL, Miller KD, Fedewa SA, et al. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1): 7–30.
  4. Berdik C. Unlocking bladder cancer. Nature. 2017; 551(7679): S34–S35.
  5. Ide H, Miyamoto H. Steroid Hormone Receptor Signals as Prognosticators for Urothelial Tumor. Dis Markers. 2015; 2015: 840640.
  6. Bladder Cancer - Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/urinb.html.
  7. Furuse H, Ozono S. Transurethral resection of the bladder tumour (TURBT) for non-muscle invasive bladder cancer: basic skills. Int J Urol. 2010; 17(8): 698–699.
  8. Cao M, Yang G, Pan J, et al. Repeated transurethral resection for non-muscle invasive bladder cancer. Int J Clin Exp Med. 2015; 8(1): 1416–1419.
  9. Ozono S, Hinotsu S, Tabata S, et al. Nara Uro-Oncology Research Group. Treated natural history of superficial bladder cancer. Jpn J Clin Oncol. 2001; 31(11): 536–540.
  10. Brożyna AA, Jóźwicki W, Skobowiat C, et al. RORα and RORγ expression inversely correlates with human melanoma progression. Oncotarget. 2016; 7(39): 63261–63282.
  11. Jóźwicki W, Brożyna AA, Siekiera J, et al. Expression of Vitamin D Receptor (VDR) Positively Correlates with Survival of Urothelial Bladder Cancer Patients. Int J Mol Sci. 2015; 16(10): 24369–24386.
  12. Cadenas C, van de Sandt L, Edlund K, et al. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 2014; 13(20): 3282–3291.
  13. Fu RD, Qiu CH, Chen HA, et al. Retinoic acid receptor-related receptor alpha (RORalpha) is a prognostic marker for hepatocellular carcinoma. Tumour Biol. 2014; 35(8): 7603–7610.
  14. Jetten AM, Ueda E. Retinoid-related orphan receptors (RORs): roles in cell survival, differentiation and disease. Cell Death Differ. 2002; 9(11): 1167–1171.
  15. Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal. 2009; 7: e003.
  16. Jetten AM, Kang HS, Takeda Y. Retinoic acid-related orphan receptors α and γ: key regulators of lipid/glucose metabolism, inflammation, and insulin sensitivity. Front Endocrinol (Lausanne). 2013; 4: 1.
  17. Cook DN, Kang HS, Jetten AM. Retinoic Acid-Related Orphan Receptors (RORs): Regulatory Functions in Immunity, Development, Circadian Rhythm, and Metabolism. Nucl Receptor Res. 2015; 2.
  18. Kallen JA, Schlaeppi JM, Bitsch F, et al. X-ray structure of the hRORalpha LBD at 1.63 A: structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of RORalpha. Structure. 2002; 10(12): 1697–1707.
  19. Chang MiRa, Dharmarajan V, Doebelin C, et al. Synthetic RORγt Agonists Enhance Protective Immunity. ACS Chem Biol. 2016; 11(4): 1012–1018.
  20. Jetten AM, Kurebayashi S, Ueda E. The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol. 2001; 69: 205–247.
  21. Moretti RM, Montagnani Marelli M, Motta M, et al. Role of the orphan nuclear receptor ROR alpha in the control of the metastatic behavior of androgen-independent prostate cancer cells. Oncol Rep. 2002; 9(5): 1139–1143.
  22. Xiong G, Wang C, Evers BM, et al. RORα suppresses breast tumor invasion by inducing SEMA3F expression. Cancer Res. 2012; 72(7): 1728–1739.
  23. Slominski AT, Kim TK, Takeda Y, et al. RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. FASEB J. 2014; 28(7): 2775–2789.
  24. Ou Z, Shi X, Gilroy RK, et al. Regulation of the human hydroxysteroid sulfotransferase (SULT2A1) by RORα and RORγ and its potential relevance to human liver diseases. Mol Endocrinol. 2013; 27(1): 106–115.
  25. Kottorou AE, Antonacopoulou AG, Dimitrakopoulos FID, et al. Altered expression of NFY-C and RORA in colorectal adenocarcinomas. Acta Histochem. 2012; 114(6): 553–561.
  26. Jóźwicki W, Skok Z, Brożyna A, et al. Urological Oncology Prognostic and diagnostic implications of histological differentiation in invasive urothelial cell carcinoma of the bladder: variant or non-classic differentiation number. Central European Journal of Urology. 2010; 63: 112–116.
  27. Domanowska E, Jozwicki W, Domaniewski J, et al. Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol. 2007; 38(5): 741–746.
  28. Jozwicki W, Domaniewski J, Skok Z, et al. Usefulness of histologic homogeneity estimation of muscle-invasive urinary bladder cancer in an individual prognosis: a mapping study. Urology. 2005; 66(5): 1122–1126.
  29. Jóźwicki W, Brożyna AA. Does stem cell marker Oct4a expression affect urothelial bladder cancer phenotype? In Sokolowska B (ed): Civilization and Social Diseases, Pope John II University in Biała Podlaska, Institute of Health: Biała Podlaska, Poland. ; 2010: 43–53.
  30. International Agency for Research on Cancer. WHO Classification of Tumours of the Urinary System and Male Genital Organs, 4th edition. Lyon: International Agency for Research on Cancer. ; 2016.
  31. Chauvet C, Vanhoutteghem A, Duhem C, et al. Control of gene expression by the retinoic acid-related orphan receptor alpha in HepG2 human hepatoma cells. PLoS One. 2011; 6(7): e22545.
  32. Fan J, Lv Z, Yang G, et al. Retinoic Acid Receptor-Related Orphan Receptors: Critical Roles in Tumorigenesis. Front Immunol. 2018; 9: 1187.
  33. Jóźwicki W, Brożyna AA, Siekiera J. Expression of OCT4A: the first step to the next stage of urothelial bladder cancer progression. Int J Mol Sci. 2014; 15(9): 16069–16082.
  34. Jetten AM, Joo JH. Retinoid-related Orphan Receptors (RORs): Roles in Cellular Differentiation and Development. Adv Dev Biol. 2006; 16: 313–355.
  35. Dong C, Yuan L, Dai J, et al. Melatonin inhibits mitogenic cross-talk between retinoic acid-related orphan receptor alpha (RORalpha) and ERalpha in MCF-7 human breast cancer cells. Steroids. 2010; 75(12): 944–951.
  36. Du J, Huang C, Zhou B, et al. Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J Immunol. 2008; 180(7): 4785–4792.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl